Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $15.1052W HIGH $909.98
Volume
40.30 K
Value Traded
1.03 M
Short % Float
5.13%
+15.07%Week
+10.84%1 Month
+91.56%3 Month
+23.26%6 Month
-99.7%5 Year
-99.85%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
34.32 M
EPS (TTM)
-90.92
P/E Ratio
-
Ent. Value
-81.67 M
Total Shares
1.02 M
Float Shares
980.00 K
Insiders
3.52%
Institutions
33.89%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
QNCX Catalyst Timeline
Dated clinical, regulatory and corporate events for Quince Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Quince Therapeutics, Inc.
113Total events
8Upcoming
24Tier-1 (high impact)
2019 to 2028Coverage
Upcoming catalysts 2
Event history 50
▲Enrollment CompleteLAM-001Trial
Phase 2 BOS trial fully enrolled
bronchiolitis obliterans syndrome post lung transplant (BOS)source ↗
◆Trial InitiationLAM-001Trial
Phase 2b trial initiation planned in PH-ILD
pulmonary hypertension associated with interstitial lung disease (PH-ILD)source ↗
▲Oral PresentationLAM-001Presentation
Phase 2a data presented at ATS conference
pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD)source ↗
▼Equity OfferingCorporate
Closed private placement financing with $115 million gross proceeds
▲Oral PresentationLAM-001Presentation
Presented Phase 2a data at ATS Conference
PAH and PH-ILDsource ↗
▲Full ResultsLAM-001Clinical Data
Phase 2a data in pulmonary hypertension presented at ATS
pulmonary hypertensionsource ↗
◆Trial InitiationLAM-001Trial
Phase 2b trial initiation planned
pulmonary hypertension associated with interstitial lung disease (PH-ILD)source ↗
▼Topline ReadouteDSPClinical Data
Topline results from pivotal Phase 3 NEAT trial of eDSP in A-T
Ataxia-Telangiectasiasource ↗
▼Program DiscontinuationeDSPCorporate
Company to cease clinical development of eDSP
Ataxia-Telangiectasiasource ↗
▼Primary Endpoint MissedeDSPClinical Data
Primary endpoint not met in NEAT trial
Ataxia-Telangiectasiasource ↗
◆Poster PresentationeDSPPresentation
Safety data from long-term eDSP treatment in children with A-T presented at BPNA 2026
Ataxia-Telangiectasiasource ↗
◆Topline ReadouteDSPClinical Data
Topline results from Phase 3 NEAT trial expected
Ataxia-Telangiectasiasource ↗
▲DSMB RevieweDSPTrial
iDSMB safety analysis recommended study continue without modifications
Ataxia-Telangiectasia (A-T)source ↗
●Poster PresentationeDSPPresentation
Poster presentation at 54th CNS Annual Meeting on patient-reported walking capacity
Ataxia-Telangiectasia (A-T)source ↗
●Oral PresentationeDSPPresentation
Virtual 2025 Investor Day held on October 2, 2025
Ataxia-Telangiectasia (A-T)source ↗
◆Topline ReadouteDSPClinical Data
Phase 3 NEAT topline results expected in Q4 2025
Ataxia-Telangiectasiasource ↗
◆Topline ReadoutEryDexClinical Data
Phase 3 NEAT topline results expected Q4 2025
Ataxia-Telangiectasiasource ↗
▲Debt Royalty FinancingCorporate
Second amendment to EIB debt agreement reducing minimum cash balance requirement
▲Enrollment CompleteeDSPTrial
Completed enrollment in pivotal Phase 3 NEAT clinical trial with 105 participants
Ataxia-Telangiectasia (A-T)source ↗
▲Enrollment CompleteeDSPTrial
Completed enrollment in pivotal Phase 3 NEAT trial
Ataxia-Telangiectasiasource ↗
▲Enrollment CompleteeDSPTrial
Completed enrollment in pivotal Phase 3 NEAT trial with 105 participants
Ataxia-Telangiectasia (A-T)source ↗
◆Enrollment CompleteeDSPTrial
Potential early conclusion of enrollment for Phase 3 NEAT trial
Ataxia-Telangiectasiasource ↗
◆Enrollment CompleteeDSPTrial
Target enrollment completion expected in Q2 2025
Ataxia-Telangiectasiasource ↗
▲Enrollment MilestoneeDSPTrial
Phase 3 NEAT trial exceeds 50% enrollment with 61 participants randomized
Ataxia-Telangiectasiasource ↗
▲Patent GrantedeDSPIP / Competition
Notice of Allowance from USPTO extending patent claims into 2036
Ataxia-Telangiectasiasource ↗
●Oral PresentationeDSPPresentation
Post hoc data analyses from prior Phase 3 ATTeST trial presented at 2025 A-T Clinical Research Conference
Ataxia-Telangiectasia (A-T)source ↗
◆Trial InitiationeDSPTrial
Phase 2 DMD study initiation planned in 2025
Duchenne muscular dystrophysource ↗
●Timing GuidanceEryDexPresentation
NDA submission targeted by end of 2025
Ataxia-Telangiectasia (A-T)source ↗
◆Trial InitiationEryDexTrial
Plan to initiate DMD proof-of-concept study in 2025
Duchenne muscular dystrophysource ↗
▲Enrollment UpdateEryDexTrial
32 patients enrolled in Phase 3 NEAT trial
Ataxia-Telangiectasiasource ↗
●Poster PresentationEryDexPresentation
Two poster presentations at 2024 International Congress for Ataxia Research in November 2024
Ataxia-Telangiectasiasource ↗
Past FDA Catalysts and PDUFA Decisions
How QNCX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-06-30 | EryDex (intra-erythrocyte dexamethasone sodium phosphate) | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C44 / 100
Pipeline Score
$14M
Pipeline Value
Overvalued
Valuation Signal
2
Drugs Scored
0.5x
rNPV / MCap
Top 30%
Micro Cap(rank 198 of 658)
Percentile Rank
Quince Therapeutics, Inc. carries a moderate pipeline score (44/100), with $619M risk-adjusted pipeline value, led by EryDex in Nervous System Disease (Phase 3), across $157B in total addressable markets.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EryDex Small moleculeCompletedNCT02770807 | Nervous System Disease | Phase 3 | COMPLETED | 176 | May 13, 2021 |
Clinical Trial Results
Readouts, endpoints and source filings for every QNCX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| LAM-001 | pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) | Phase 2a | 2026-05-18 | 6MWD increase: 67.4 meters; PVR reduction: 33.9%Read More | UPDATE - Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILDRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Benatti LucaDirector | Sell | -50,000 39,179 held | $3.47 | 12/26/2025 |
Hedge Fund 13F Activity
Hedge Funds invested in QNCX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 0 % (-100 %) | 245.00 K | 184.38 K | -87.71% ( -1.32 M) |
QNCX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How QNCX ranks across every disease it competes in
Competitive Position is a premium feature
See how QNCX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialQNCX News
-QNCX
Oct 9, 2026▲ +14.9%today
Quince Therapeutics Relaunches as IRulya Therapeutics with a Focus on the Clinical Development of LAM-001, Targeting a Key Pathway in Pulmonary Disease
Quince Therapeutics has rebranded as IRulya Therapeutics, focusing on the clinical development of LAM-001, an inhaled rapamycin formulation for pulmonary diseases. The company has announced key management changes and a strong cash position expected to fund operations through 2028. LAM-001 is currently in Phase 2 trials for multiple indications, including PH-ILD, BOS, and SAPH.
Read more →-QNCX
Sep 17, 2026Quince Therapeutics to Host Virtual KOL Event to Discuss the Current Treatment Landscape for PH-ILD and BOS and the Role for LAM-001 as a Potential Therapeutic Option on September 28, 2026
Quince Therapeutics will host a virtual KOL event on September 28, 2026, to discuss the treatment landscape for pulmonary hypertension associated with interstitial lung disease (PH-ILD) and bronchiolitis obliterans syndrome (BOS). Experts will highlight LAM-001, an investigational inhaled formulation of rapamycin, which is currently in Phase 2 trials. The event aims to address unmet medical needs and showcase the potential of LAM-001 as a disease-modifying therapy.
Read more →-QNCX
Sep 3, 2026Quince Therapeutics to Participate in September 2026 Investor Conferences
Quince Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in two investor conferences in September 2026. The events include a fireside chat at the Cantor Global Healthcare Conference and a presentation at the H.C. Wainwright 28th Annual Global Investment Conference. The company is focused on developing disease-modifying therapies for serious conditions.
Read more →-QNCX
Aug 14, 2026▲ +5%on this news
Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update
Quince Therapeutics reported its second quarter 2026 financial results, highlighting the acquisition of Orphai Therapeutics and the addition of LAM-001 to its pipeline. The company anticipates Phase 2b data for LAM-001 in pulmonary hypertension associated with interstitial lung disease by early 2028. Despite a net loss of $75.5 million, Quince maintains a strong cash position of $116 million, expected to support operations through 2028.
Read more →-QNCX
Jun 30, 2026Quince Therapeutics Appoints Recognized Leaders in Pulmonary Medicine to Scientific Advisory Board
Quince Therapeutics has established a Scientific Advisory Board (SAB) comprising experts in pulmonary medicine to advance the development of LAM-001, an inhaled formulation of rapamycin. The SAB will focus on multiple pulmonary indications, including pulmonary hypertension associated with interstitial lung disease. The company is optimistic about LAM-001's potential benefits based on positive Phase 2a trial results.
Read more →-QNCX
May 18, 2026▼ -13.5%on this news
UPDATE - Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD
Quince Therapeutics announced positive results from its Phase 2a study of LAM-001, an inhaled mTOR inhibitor, in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The study demonstrated significant improvements in lung function, including a 67.4-meter increase in six-minute walk distance (6MWD) and a 33.9% reduction in pulmonary vascular resistance (PVR). A Phase 2b trial is set to begin in mid-2026, with topline data expected in early 2028.
Read more →-QNCX
May 18, 2026▼ -13.5%on this news
Quince Announces Acquisition of Orphai and up to $187 Million Private Placement to Advance Pulmonary Pipeline
Quince Therapeutics has acquired Orphai Therapeutics, gaining access to LAM-001, an inhaled rapamycin formulation targeting rare pulmonary diseases. The acquisition is supported by a $187 million private placement, with $115 million upfront. Quince plans to initiate Phase 2b trials for pulmonary hypertension associated with interstitial lung disease and bronchiolitis obliterans syndrome, with data expected in 2027 and 2028.
Read more →-QNCX
May 18, 2026▼ -13.5%on this news
Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD Data from Phase 2a study of LAM-001 on top of standard of care in
Quince Therapeutics, Inc. announced promising results from its Phase 2a study of LAM-001, an inhaled formulation aimed at treating patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The study showed significant improvements across various clinical endpoints, including a notable increase in the six-minute walk distance (6MWD) and reductions in pulmonary vascular resistance (PVR). The data supports LAM-001's potential as an effective therapy in this area of unmet medical need. The company plans to advance LAM-001 into a Phase 2b trial later this year.
Read more →-QNCX
Mar 30, 2026▲ +15.6%on this news
Quince Therapeutics Settles Approximately $16.4 Million of Debt
Quince Therapeutics has settled approximately $16.4 million of debt. This financial move may impact the company's balance sheet positively, but further details on the implications for operations or future plans are not provided.
Read more →-QNCX
Feb 9, 2026▲ +305.9%on this news· ran to +369% by day 1
Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives
Quince Therapeutics has appointed LifeSci Capital as its exclusive financial advisor to assist in exploring strategic alternatives aimed at maximizing shareholder value. These alternatives may include partnerships, mergers, or other transactions. The company will not disclose further developments until specific actions are approved by its Board of Directors.
Read more →-QNCX
Jan 30, 2026▼ -37.1%on this news
Quince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia
Quince Therapeutics announced that its pivotal Phase 3 NEAT trial for eDSP in Ataxia-Telangiectasia did not meet its primary or key secondary endpoints, leading the company to halt further development of the drug. Despite the lack of efficacy, eDSP was well tolerated with no major safety issues reported. The company aims to preserve cash and explore other options.
Read more →-QNCX
Jan 29, 2026Quince Therapeutics Presents Safety Data from Long-Term eDSP Treatment in Children with Ataxia-Telangiectasia at British Paediatric Neurology Association Annual Meeting
Quince Therapeutics presented safety data from a long-term study of encapsulated dexamethasone sodium phosphate (eDSP) for children with Ataxia-Telangiectasia (A-T) at the British Paediatric Neurology Association Annual Meeting. The analysis focused on the safety profile of eDSP, which has been administered for at least two years. The company is advancing a Phase 3 clinical trial for eDSP and expects to report topline results in early 2026.
Read more →-QNCX
Nov 12, 2025Quince Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
Quince Therapeutics recently provided an update detailing its financial results for Q3 2025 and the status of its pivotal Phase 3 NEAT clinical trial for eDSP, aimed at treating Ataxia-Telangiectasia. The trial remains on track, with topline results anticipated in the first quarter of 2026. Positive insights include a favorable safety analysis from an independent monitoring board and full participation in the open label extension study. However, the company reported a net loss, indicating ongoing financial pressures as they prepare for future regulatory submissions.
Read more →-QNCX
Aug 11, 2025Quince Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results
Quince Therapeutics announced a significant milestone with the completion of enrollment in its Phase 3 NEAT clinical trial for eDSP, aimed at treating Ataxia-Telangiectasia (A-T). The company also reported a cash position of approximately $35 million following a recent financing round, expected to support operations through key upcoming trial results. Additionally, Quince formed a partnership with Option Care Health to facilitate the U.S. launch of eDSP. Despite these advancements, the company reported a net loss of $16.1 million for the second quarter of 2025.
Read more →-QNCX
Jul 16, 2025Quince Therapeutics Completes Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia
Quince Therapeutics has successfully completed enrollment in the pivotal Phase 3 NEAT clinical trial for its lead product, eDSP, aimed at treating Ataxia-Telangiectasia (A-T). This milestone is significant for the company as it moves closer to potentially delivering a first treatment for this rare disease. The CEO expressed confidence in the trial's design and oversight, with topline results expected in early 2026, followed by an NDA submission later that year. A-T is a severe neurodegenerative disorder with no currently approved therapies.
Read more →-QNCX
May 13, 2025Quince Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results
Quince Therapeutics provided a business update and reported its first quarter 2025 financial results, revealing plans for the Phase 3 NEAT clinical trial for Ataxia-Telangiectasia. The company may conclude enrollment early by June 2025 to better align topline results with its existing cash runway. While enrollment has been slower than expected due to various challenges, the company remains hopeful for positive trial results and subsequent regulatory submissions in 2026. Quince reported a net loss of $15 million for this quarter, prompting a focus on strategic funding solutions to maintain operations.
Read more →-QNCX
Mar 24, 2025Quince Therapeutics Provides Business Update and Reports Fiscal Year 2024 Financial Results
Quince Therapeutics announced a significant update regarding its Phase 3 NEAT clinical trial, reporting over 50% enrollment and expecting new site activations to further boost participant screenings. The company's fiscal year 2024 financial results showed a cash position of $40.8 million, projected to sustain operations into 2026. Despite reporting a net loss for the year, Quince is progressing with plans for additional studies and has established a dedicated Scientific Advisory Board. The anticipated topline results from the NEAT trial are expected in the fourth quarter of 2025.
Read more →-QNCX
Nov 13, 2024Quince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results Phase 3 NEAT clinical trial on track with 32 patients enrolled to date with majority of U.S. and European study sites now enro
Quince Therapeutics has reported a positive update regarding its Phase 3 NEAT clinical trial, noting that 32 patients have been enrolled to date. The company expects to maintain enrollment momentum and aims to complete it by Q2 2025, with topline results anticipated in Q4 2025. Additionally, Quince provided its third quarter financial results, revealing a net loss of $5.5 million, but it maintains a strong cash position sufficient to fund operations into 2026.
Read more →About Quince Therapeutics, Inc.
Headquarters611 GATEWAY BLVD., SUITE 273, SOUTH SAN FRANCISCO, CA, 94080
BIOPHARMAWATCH ELITE PLUS
Trade the next QNCX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime